Microencapsulated parathyroid allotransplantation in the omental tissue.
biocompatible polymer
microencapsulation
parathyroid allotransplantation
parathyroid hormone
permanent hypoparathyroidism
ultrapure alginate
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
19
12
2018
revised:
28
02
2019
accepted:
18
04
2019
pubmed:
24
4
2019
medline:
23
2
2020
entrez:
24
4
2019
Statut:
ppublish
Résumé
Permanent hypoparathyroidism is a severe clinical condition accompanied by low parathyroid hormone level. Conventional treatment requires lifelong medication, and daily drug usage has some side effects. To avoid this circumstance, transplantation is an alternative and curative option. Microencapsulation may be used as a transplantation approach particularly to evade immune response. In order to define treatment of permanent hypoparathyroidism, a 37-year-old female recipient who has permanent hypoparathyroidism was evaluated for 3 years. Routine tests, viral markers, and T and B lymphocyte cross-match tests were analyzed. In addition intradermal skin test was performed for ultrapure alginate. Microencapsulation of cultured parathyroid cells was performed with ultrapure alginate. Cell suspension was prepared and spheroids were generated with calcium chloride. Afterward, transplantation was performed with a laparoscopic approach in the omental tissue. The recipient was discharged from the hospital without complications. Serum calcium, parathyroid hormone (PTH), and phosphorus levels were observed throughout 1 year. During the follow-up period, no complications were observed. Serum calcium levels were increased significantly on day 10 and PTH levels were increased on day 25 as well. According to our knowledge, this is the first study where ultrapure alginate-based microencapsulated parathyroid cells were transplanted in the omental tissue. A significant increment of PTH levels was detected. Microencapsulated parathyroid cells showed the functionality of this technique for more than 1 year. This study showed that using ultrapure alginate-based microencapsulation without immunosuppression appears to be a promising technique.
Substances chimiques
Alginates
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1022-1027Subventions
Organisme : Bezmialem Vakif University
ID : 32015-19
Informations de copyright
© 2019 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
Références
Rejnmark L, Underbjerg L, Hypoparathyroidism Sikjaer T. Replacement therapy with parathyroid hormone. Endocrinol Metab (Seoul, Korea). 2015;30:436-42.
Abate EG, Clarke BL. Review of hypoparathyroidism. Front Endocrinol. 2016;7:172.
Aysan E, Altug B, Ercan C, Kesgin Toka C, Idiz UO, Muslumanoglu M. Parathyroid allotransplant with a new technique: a prospective clinical trial. Exp Clin Transplant. 2016;14:431-5.
Giordano D, Valcavi R, Thompson GB, Pedroni C, Renna L, Gradoni P, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid. 2012;22:911-7.
Tartaglia F, Giuliani A, Sgueglia M, Biancari F, Juvonen T, Campana FP. Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy. Am J Surg. 2005;190:424-9.
Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract. 2011;17 Suppl 1:18-25.
Safioleas M, Stamatakos M, Rompoti N, Mouzopoulos G, Iannescu R, Salichou V, et al. Complications of thyroid surgery. Chirurgia (Bucur). 2006;101:571-81.
Recombinant human parathyroid hormone (Natpara). Med Lett Drugs Ther. 2015;57:87-8. PMID: 26035748.
Collinge C, Favela J. Use of teriparatide in osteoporotic fracture patients. Injury. 2016;47 Suppl 1:S36-8.
Nawrot I, Wozniewicz B, Tolloczko T, Sawicki A, Gorski A, Chudzinski W, et al. Allotransplantation of cultured parathyroid progenitor cells without immunosuppression: clinical results. Transplantation. 2007;83:734-40.
Cabane P, Gac P, Amat J, Pineda P, Rossi R, Caviedes R, et al. Allotransplant of microencapsulated parathyroid tissue in severe postsurgical hypoparathyroidism: a case report. Transpl Proc. 2009;41:3879-83.
Khryshchanovich V, Ghoussein Y. Allotransplantation of macroencapsulated parathyroid cells as a treatment of severe postsurgical hypoparathyroidism: case report. Ann Saudi Med. 2016;36:143-7.
Mooranian A, Negrulj R, Arfuso F,Al-Salami H. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells. Artif Cells Nanomed Biotechnol. 2016;44:194-200.
de Vos P, Lazarjani HA, Poncelet D, Faas MM. Polymers in cell encapsulation from an enveloped cell perspective. Adv Drug Deliv Rev. 2014;67-68:15-34.
Lu B, Gao Q, Liu R, Ren M, Wu Y, Jiang Z, et al. Effect of a new drug releasing system on microencapsulated islet transplantation. Int J Clin Exp Pathol. 2015;8:12390-9.
Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev. 2012;64 Suppl:194-205.
Paredes Juárez GA, Spasojevic M, Faas MM, de Vos P. Immunological and technical considerations in application of alginate-based microencapsulation systems. Front Bioeng Biotechnol. 2014;2:26.
Gasperini L, Mano JF, Reis RL. Natural polymers for the microencapsulation of cells. J R Soc Interface. 2014;11:20140817.
Paredes Juarez GA, Spasojevic M, Faas MM, de Vos P. Immunological and technical considerations in application of alginate-based microencapsulation systems. Front Bioeng Biotechnol. 2014;2:26.
Vegas AJ, Veiseh O, Gurtler M, Millman JR, Pagliuca FW, Bader AR, et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med. 2016;22:306.
Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006;29:137-8.
Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009;32:1887-9.
Basta G, Montanucci P, Luca G, Boselli C, Noya G, Barbaro B, et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care. 2011;34:2406-9.
Agha A, Scherer MN, Moser C, Karrasch T, Girlich C, Eder F, et al. Living-donor parathyroid allotransplantation for therapy-refractory postsurgical persistent hypoparathyroidism in a nontransplant recipient - three year results: a case report. BMC Surg. 2016;16:51.
Murua A, Portero A, Orive G, Hernandez RM, de Castro M, Pedraz JL. Cell microencapsulation technology: towards clinical application. J Controlled Release. 2008;132:76-83.
Tolloczko T, Wozniewicz B, Gorski A, Sawicki A, Nawrot I, Migaj M, et al. Cultured parathyroid cells allotransplantation without immunosuppression for treatment of intractable hypoparathyroidism. Ann Transplant. 1996;1:51-3.
Barczynski M, Golkowski F, Nawrot I. Parathyroid transplantation in thyroid surgery. Gland Surg. 2017;6:530-6.
Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation. 2007;14:157-61.
Hermosillo-Sandoval JM, Leonher-Ruezga KL, Jimenez-Gomez JA, Fuentes-Orozco C, Gonzalez-Ojeda A, Ramirez-Gonzalez LR. Allogeneic parathyroid: 2-year follow-up. Cir Cir. 2015;83:188-92.
Nawrot I, Wozniewicz B, Szmidt J, Sladowski D, Zajac K, Chudzinski W. Xenotransplantation of human cultured parathyroid progenitor cells into mouse peritoneum does not induce rejection reaction. Cent Eur J Immunol. 2014;39:279-84.